Presenting at a prestigious congress like EBMT can significantly enhance a company's reputation in the medical community, potentially leading to increased interest from investors and partners. The focus on CD19 CAR-T studies, a cutting-edge area in cancer treatment, suggests Galapagos is making meaningful progress in its oncology pipeline. This could positively impact investor sentiment and the company's stock price in the short term, assuming the data presented is favorable.